Sethu Sankaranarayanan is an accomplished scientist with broad experience in drug discovery and neurodegenerative disease. He obtained a PhD in neuroscience from Washington State University and pursued postdoctoral research experiences at the Max-Planck Institute in Heidelberg and the Weill Medical College of Cornell University. Dr. Sankaranarayanan heads the translational biomarkers group at Nine Square. He previously held scientific leadership roles at early-stage biotech and pharmaceutical companies, including Escape Bio, Annexon, Bristol-Myers Squibb and Merck. During his tenure at these organizations, Dr. Sankaranarayanan led the discovery and development of both small molecule and antibody-based therapies and biomarkers for diverse areas such as neurodegeneration, ophthalmology and autoimmune disease. He has contributed significantly to the successful progression of several molecules from early discovery to clinical studies.